Showing results (11-20 of 221) with videos related to
Sort By:
Pageof 23
Frontiers in Oncology|March 3, 2022
Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck CancerBrennan Olson, Jared Edwards, Catherine Degnin, et al.Optics Express|June 17, 2009
A family of approximations spanning the Born and Rytov scattering seriesDaniel L MarksJournal of Cachexia, Sarcopenia and Muscle|October 28, 2022
Lipopolysaccharide-induced hypothalamic inflammation in cancer cachexia-anorexia is amplified by tumour-derived prostaglandin E2Xiaolin Li, Tosca Holtrop, Fleur A C Jansen, et al.Brain, Behavior, and Immunity|September 10, 2019
Persistent Toll-like receptor 7 stimulation induces behavioral and molecular innate immune toleranceKatherine A Michaelis, Mason A Norgard, Peter R Levasseur, et al.Journal of Nutrition Education and Behavior|September 1, 2016
Compliance With Recommended Food Safety Practices in Television Cooking ShowsNancy L Cohen, Rita Brennan OlsonCurrent Opinion in Clinical Nutrition and Metabolic Care|April 20, 2011
Hypothalamic regulation of muscle metabolismTheodore P Braun, Daniel L MarksExpert Opinion on Investigational Drugs|September 28, 2005
The use of melanocortin antagonists in cachexia of chronic diseaseJarrad M Scarlett, Daniel L MarksBrain, Behavior, and Immunity|July 10, 2021
Chronic cerebral lipocalin 2 exposure elicits hippocampal neuronal dysfunction and cognitive impairmentBrennan Olson, Xinxia Zhu, Mason A Norgard, et al.Current Opinion in Supportive and Palliative Care|August 25, 2010
Neuropeptides in the pathophysiology and treatment of cachexiaStephanie M Krasnow, Daniel L MarksNature Clinical Practice. Endocrinology & Metabolism|August 26, 2006
Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic diseaseMark D DeBoer, Daniel L MarksPageof 23